IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer
This study is ongoing, but not recruiting participants.
Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Brigham and Women's Hospital
Saint Anne's Hospital
Beth Israel Deaconess Medical Center
Metro West Medical Center
Information provided by (Responsible Party):
Anthony V. D'Amico, MD, PhD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00116220
First received: June 27, 2005
Last updated: July 25, 2017
Last verified: July 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This clinical study was to determine if the use of 6 months of total androgen suppression (hormonal therapy) when added to radiation therapy for localized-high risk prostate cancer would improve overall survival.
| Condition | Intervention | Phase |
|---|---|---|
| Prostate Cancer | Drug: Flutamide (Eulexin) and Lupron or Zoladex Radiation: External Beam Radiotherapy | Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment |
| Official Title: | A Phase III Trial of External Beam of Radiotherapy +/- Total Androgen Suppression for High Risk Clinically Organ-Confined Prostate Cancer |
Resource links provided by NLM:
Genetics Home Reference related topics:
prostate cancer
MedlinePlus related topics:
Prostate Cancer
Drug Information available for:
Flutamide
U.S. FDA Resources
Further study details as provided by Anthony V. D'Amico, MD, PhD, Dana-Farber Cancer Institute:
Primary Outcome Measures:
- To determine if the 2 year freedom from PSA failure is increased in patients receiving total androgen suppression and radiation therapy compared to those patients receiving radiation therapy alone. [ Time Frame: Years ]
Secondary Outcome Measures:
- Evaluate the quality of life of patients receiving total androgen suppression and radiation therapy [ Time Frame: Years ]
| Enrollment: | 226 |
| Study Start Date: | September 1995 |
| Estimated Study Completion Date: | September 2018 |
| Primary Completion Date: | April 2001 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Treatment 1
External beam radiation therapy + 6 months total androgen ablation
|
Drug: Flutamide (Eulexin) and Lupron or Zoladex
Androgen suppression therapy
Radiation: External Beam Radiotherapy
Once a day, 4-5 days per week for approximately 2 months
|
|
Active Comparator: Treatment 2
External beam radiation therapy
|
Radiation: External Beam Radiotherapy
Once a day, 4-5 days per week for approximately 2 months
|
Detailed Description:
This was a randomized study comparing external beam radiation therapy with total androgen ablation for 6 months with radiation therapy alone. Drugs were given 2 months prior, 2 months during, and 2 months after radiation therapy. Eulexin and Lupron or Zoladex was used in this study.
Eligibility| Ages Eligible for Study: | 41 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Biopsy proven prostate cancer
- Negative bone scan
- Lymph nodes by CT or MRI
- Adequate blood work
- Performance Status - ECOG 0-1
- Life expectancy of at least 10 years
- >40 years of age
Exclusion Criteria:
- Prior history of malignancy
- Prior hormonal therapy or chemotherapy
- Prior pelvic radiation therapy
- Unable to tolerate lying still 5-10 minutes/day
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00116220
Please refer to this study by its ClinicalTrials.gov identifier: NCT00116220
Locations
| United States, Massachusetts | |
| Dana-Farber Cancer Institute | |
| Boston, Massachusetts, United States, 02115 | |
Sponsors and Collaborators
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Saint Anne's Hospital
Beth Israel Deaconess Medical Center
Metro West Medical Center
Investigators
| Principal Investigator: | Anthony V D'Amico, M.D. Ph.D. | Dana-Farber Cancer Institute |
More Information
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Anthony V. D'Amico, MD, PhD, Principal Investigator, Dana-Farber Cancer Institute |
| ClinicalTrials.gov Identifier: | NCT00116220 History of Changes |
| Other Study ID Numbers: |
95-096 |
| Study First Received: | June 27, 2005 |
| Last Updated: | July 25, 2017 |
Keywords provided by Anthony V. D'Amico, MD, PhD, Dana-Farber Cancer Institute:
|
Prostate Cancer Total Androgen Suppression endorectal coil MRI External Beam Radiation Therapy Prostate Cancer- High Risk, clinically Organ-Confined |
Additional relevant MeSH terms:
|
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Genital Diseases, Male Prostatic Diseases Androgens Goserelin |
Flutamide Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents Androgen Antagonists Hormone Antagonists |
ClinicalTrials.gov processed this record on August 17, 2017